A novel antibiotic complex has been isolated from the fermentation broth of a new species of Actinomadura, A. kijaniata SCC 1256. The complex was separated from the broth by a solvent extraction procedure and consists of 1 major component, designated kijanimicin, and 3 minor components.
In the course of our screening for novel antibiotic producing organisms, a culture was noted that appeared distinct in pigmentation from cultures previously observed. This strain, designated SCC 1256, was found to be producing a complex of novel antibiotics from which the major component, designated kijanimicin (Sch 25663) was separated. These antibiotics were active against an unusual spectrum of microorganisms including anaerobes, particulary Propionibacterium acnes. In vivo activity against Plasmodium berghei and P. chabaudi in mice was also observed. This paper details the fermentation and isolation of the antibiotic complex, as well as purification, identification, characterization, 14C labelling, and biological activity of the major component, kijanimicin. Details of the taxonomic evaluation of the producing organism as well as chemical structure elucidation appear elsewhere1-3) .
Producing Culture
The producing culture was isolated from a soil sample collected in Kenya. The culture has been identified as a new species of the genus Actinomadura, designated A, kijaniata'~. The strain has been deposited in the American Type Culture Collection, Rockville, Maryland, U.S.A. and has been assigned accession number ATCC 31588.
Production of Kijanimicin
The medium used for the preparation of the inoculum for antibiotic production consisted of 0.3 beef extract, 0.5% tryptose, 0.1% dextrose, 2.4% potato starch and 0.2% calcium carbonate. The pH of this medium was adjusted to 7.2 prior to sterilization. A 300 ml Erlenmeyer flask containing 70 ml of this medium was inoculated with 5 ml of the stock suspension of the producing strain maintained at -20°C.
The flask was incubated at 30°C on a rotary shaker at 250 rpm for 48 hours.
The resulting seed culture (25 ml) was transferred to a 2-liter Erlenmeyer flask containing 500 ml of the same seed medium and incubation was carried out under identical conditions for 48 hours. water. The UV absorption spectrum in methanol (Fig. 2) shows peaks at 239, 264, and 274 nm with The Rf values of kijanimicin on Whatman No. 1 paper and on Analtech Silica Gel GF thin-layer plates in several solvent systems are given in Table 1 . Kijanimicin is stable in buffered solution from pH 6 N 8 at room temperature and up to 100°C for at least 30 minutes. It loses activity immediately at room temperature at pH 2 3 and pH 9 10.
The total structure and absolute configuration of kijanimicin is reported separately by MALLAMS et aL2's~ It has been shown by chemical degradation, spectroscopic studies and X-ray crystallographic studies to have a novel tetronic acid structure. The molecule has a branched tetrasaccharide unit as well as a novel nitrosugar moiety glycosidically linked to the aglycone.
From the above data it is concluded that kijanimicin is a new antibiotic belonging to the tetrocarcin4'a~ and antlermicine'7~ family.
14C-Labelling of Kijanimicin
Incorporation of [1-14C] A 10-liter fermentation, using [1-14C]sodium propionate as radiolabelled precursor was performed to prepare 14C-kijanimicin. The same fermentation procedures as described above were used, except for addition of 8.7 mCi [1-14C]sodium propionate at 48 hours and harvesting at 72 hours. Crude antibiotic isolated from the fermentation broth weighed 7.8g. 14C-Kijanimicin was isolated following silica gel column chromatography of the crude antibiotic complex. The final product weighed 1.73 g, and showed a total radioactivity of 646 ,uCi and a specific radioactivity of 0.24 ,uCi/mg.
Biological Properties
Kijanimicin was shown to have good activity against Propionibacterium acnes and generally weaker activity against other organisms tested. In vivo it showed interesting activity against malaria.
In vitro dilution tests to determine minimum inhibitory concentrations (MICs) were done using thioglycollate broth for Gram-positive, Gram-negative, and anaerobic organisms and SABOURAUDdextrose broth for fungi. The results shown in Table 2 indicate that kijanimicin has good activity against the 24 strains of P. acnes studied. It was three times more potent than tetracycline and approximately 1/3 as active as clindamycin in vitro. The antibiotic has weak activity against other anaerobes, aerobic Gram-positive bacteria, and dermatophytes but shows good activity against B.
subtilis. It was not active against Gram-negative bacteria and yeasts at the concentrations tested.
The antibiotic was found to be effective in vivo against rodent malaria. A series of experiments were done using three different strains of Plasmodium berghei and one strain of P. chabaudi utilizing the sodium salt or free acid of kijanimicin. Mice were infected intraperitoneally and treated subcutaneously or orally either before or after infection for up to 5 days. A representative experiment is shown in Table 3 .
The antibiotic was as active as daraprim when the mice were treated 3 days post-infection with a single dose (250 mg/kg) or with multiple doses (50 mg/kg for five days). Other experiments showed kijanimicin to have activity similar to chloroquine and primaquine but less than that of quinacrine and mefloquine. The compound was not effective orally. 
